Isabelle Lousada
Overview
Explore the profile of Isabelle Lousada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dorbala S, Adigun R, Alexander K, Brambatti M, Cuddy S, Dispenzieri A, et al.
JACC Cardiovasc Imaging
. 2025 Feb;
PMID: 39985507
Light chain amyloidosis and transthyretin amyloidosis are rare protein misfolding disorders characterized by amyloid deposition in organs, varied clinical manifestations, and poor outcomes. Amyloid fibrils trigger various signaling pathways that...
2.
Rebello S, Hsu K, Nativi-Nicolau J, Karam C, Grogan M, Lousada I, et al.
Amyloid
. 2025 Feb;
:1-10.
PMID: 39950841
Introduction: Transthyretin (ATTR) amyloidosis is an ultimately fatal disease. While approved therapies slow disease progression, the cost of care can be significant for patients. The objective of this survey was...
3.
Leung N, Comenzo R, Gillmore J, Havasi A, Kastritis E, Guthrie S, et al.
Kidney Int Rep
. 2024 Jul;
9(7):1986-1994.
PMID: 39081759
Immunoglobin light chain (AL) amyloidosis is a rare disease characterized by organ deposition of amyloid fibrils, most commonly in the heart and kidney. Disease heterogeneity necessitates organ-specific assessment to determine...
4.
Maurer M, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, Wei L, et al.
Adv Ther
. 2024 Jun;
41(7):2723-2742.
PMID: 38833142
Introduction: Hereditary transthyretin amyloidosis (ATTRv, also referred to as hATTR; ORPHA 271861) and wild-type ATTR amyloidosis (ATTRwt; ORPHA 330001) are rare, progressive, systemic protein misfolding disorders with heterogeneous clinical presentations....
5.
Signorovitch J, Zhang J, Brown D, Dunnmon P, Xiu L, Done N, et al.
Ther Innov Regul Sci
. 2024 Apr;
58(4):600-609.
PMID: 38632158
Immunoglobin light chain (AL) amyloidosis is a rare disease in which a plasma cell dyscrasia leads to deposition of insoluble amyloid fibrils in multiple organs. To facilitate development of new...
6.
Cheng R, Kittleson M, Wechalekar A, Alvarez-Cardona J, Mitchell J, Macedo A, et al.
Heart
. 2024 Jan;
110(12):823-830.
PMID: 38267197
The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due...
7.
Mauermann M, Clarke J, Litchy W, Obici L, Lousada I, Gertz M
Adv Ther
. 2023 Sep;
40(11):4695-4710.
PMID: 37658177
Systemic immunoglobulin light chain (AL) amyloidosis is a heterogeneous rare disease driven by a destructive monoclonal gammopathy and typified by misfolded immunoglobulin light and/or heavy chains which aggregate and deposit...
8.
OConnor M, Hsu K, Broderick L, McCausland K, LaGasse K, Rebello S, et al.
Patient Relat Outcome Meas
. 2023 Jul;
14:213-222.
PMID: 37441025
Purpose: Patients with transthyretin amyloidosis (ATTR) experience a wide variety of symptoms and impacts on health-related quality of life (HRQoL). However, the lack of an ATTR-specific patient-reported outcome (PRO) measure...
9.
Rizio A, White M, DSouza A, Hsu K, Schmitt P, Quock T, et al.
Patient Relat Outcome Meas
. 2023 May;
14:153-169.
PMID: 37229285
Systemic AL (light chain) amyloidosis is a rare protein misfolding disorder associated with plasma cell dyscrasia affecting various organs leading to organ dysfunction and failure. The Amyloidosis Forum is a...
10.
Maurer M, Dunnmon P, Fontana M, Quarta C, Prasad K, Witteles R, et al.
Circ Heart Fail
. 2022 Mar;
15(6):e009038.
PMID: 35331001
Immunoglobulin light chain amyloidosis is a rare, multisystemic, phenotypically heterogenous disease affecting cardiovascular, renal, neurological, and gastrointestinal systems to varying degrees. Its underlying cause is a plasma cell dyscrasia characterized...